Clinical Trials Browser

Phase 3 × Ipilimumab × Clear all

NCT02506153 2026-03-18

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,301 enrolled 16 charts

Melanoma

NCT03793166 2026-03-18

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Phase 3 Active not recruiting

Carcinoma, Renal Cell, Lymphatic Metastasis

NCT03036098 2026-03-06

CheckMate901

Phase 3 Active not recruiting

1,314 enrolled 23 charts 1 FDA

Urothelial Cancer

NCT06097728 2026-03-04

eVOLVE-Meso

Phase 3 Recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT04039607 2026-02-19

CheckMate 9DW

Phase 3 Active not recruiting

732 enrolled 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT01274338 2026-02-18

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,673 enrolled 19 charts

Melanoma

NCT02224781 2026-02-18

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Phase 3 Active not recruiting

267 enrolled 8 charts

Melanoma

NCT03143153 2026-02-17

CheckMate 648

Phase 3 Completed

970 enrolled 15 charts 1 FDA

Various Advanced Cancer

NCT04334759 2026-01-22

DREAM3R

Phase 3 Completed

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT07338981 2026-01-14

The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.

Phase 3 Not yet recruiting

Advanced Kidney Cancer

NCT02998528 2026-01-06

CheckMate 816

Phase 3 Completed

505 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03215706 2025-12-17

CheckMate 9LA

Phase 3 Completed

719 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03391869 2025-12-17

Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06794775 2025-12-12

SWE-NEO

Phase 3 Recruiting

Melanoma

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT03469960 2025-11-18

DICIPLE

Phase 3 Completed

Non-Small Cell Lung Cancer Metastatic

NCT02477826 2025-10-30

CheckMate 227

Phase 3 Completed

2,747 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03520686 2025-10-16

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04008030 2025-10-03

CheckMate 8HW

Phase 3 Active not recruiting

839 enrolled 22 charts 1 FDA

Gastrointestinal

Colorectal Neoplasms

NCT03937219 2025-09-10

COSMIC-313

Phase 3 Active not recruiting

855 enrolled 12 charts

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT06490536 2025-08-29

The Sagittarius Trial

Phase 3 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT02872116 2025-08-07

CheckMate649

Phase 3 Completed

2,031 enrolled 19 charts 1 FDA

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT02231749 2025-06-26

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Phase 3 Completed

1,390 enrolled 18 charts 1 FDA

Carcinoma, Renal Cell

NCT03141177 2025-06-06

CheckMate 9ER

Phase 3 Active not recruiting

701 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT01844505 2025-05-21

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Phase 3 Completed

945 enrolled 19 charts

Melanoma

NCT02388906 2025-04-24

CheckMate 238

Phase 3 Completed

906 enrolled 16 charts 1 FDA

Melanoma

NCT06364631 2025-01-16

CARE1

Phase 3 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03138512 2024-12-18

CheckMate 914

Phase 3 Completed

1,641 enrolled 21 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT04340193 2024-11-26

CheckMate 74W

Phase 3 Completed

26 enrolled 15 charts

Gastrointestinal

Liver Neoplasms

NCT06519266 2024-11-25

SCANDIUM-III

Phase 3 Recruiting

Uveal Melanoma

NCT05144854 2024-09-05

A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Phase 3 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT02899299 2024-05-21

CheckMate743

Phase 3 Completed

605 enrolled 17 charts 2 FDA

Other solid neoplasmThoracic

Mesothelioma

NCT04949113 2024-03-08

NADINA

Phase 3 Active not recruiting

Melanoma

NCT02864251 2023-09-28

CheckMate722

Phase 3 Completed

367 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT03302234 2023-09-26

KEYNOTE-598

Phase 3 Completed

568 enrolled 20 charts

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02741570 2023-09-21

CheckMate 651

Phase 3 Completed

947 enrolled 19 charts

Head and Neck Neoplasms

NCT04741438 2023-08-30

RAR-Immune

Phase 3 Unknown

Sarcoma

NCT03700905 2023-05-23

IMSTAR-HN

Phase 3 Unknown

Head and Neck Neoplasms

NCT03351361 2023-03-01

eNERGY

Phase 3 Completed

Advanced Non Small Cell Lung Cancer

NCT02538666 2023-01-05

CheckMate 451

Phase 3 Completed

907 enrolled 17 charts

Lung Neoplasms

NCT03445533 2022-11-08

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Phase 3 Terminated

481 enrolled 22 charts

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT02714218 2022-06-24

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Phase 3 Completed

387 enrolled 28 charts

Melanoma

NCT03068455 2021-09-20

CheckMate 915

Phase 3 Completed

1,844 enrolled 14 charts

Melanoma

NCT02599402 2021-06-15

CheckMate 401

Phase 3 Completed

533 enrolled 19 charts

Melanoma

NCT01450761 2020-07-08

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Phase 3 Completed

1,351 enrolled 10 charts

Small Cell Lung Carcinoma

NCT01866319 2020-06-02

MK-3475-006

Phase 3 Completed

834 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT02545075 2020-05-19

A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine

Phase 3 Completed

182 enrolled 20 charts

Melanoma

NCT03048136 2018-04-17

CheckMate 955

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT00861614 2016-09-30

Study of Immunotherapy to Treat Advanced Prostate Cancer

Phase 3 Completed

988 enrolled 19 charts

Prostatic Neoplasms

NCT01057810 2016-08-18

Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Phase 3 Completed

837 enrolled 15 charts

Prostatic Neoplasms